Back to top
more

Stevanato Group (STVN)

(Delayed Data from NYSE)

$27.54 USD

27.54
335,568

+0.02 (0.07%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $27.50 -0.04 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Stevanato Group (STVN) to Report Q1 Results: What You Should Expect

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TAK or STVN: Which Is the Better Value Stock Right Now?

TAK vs. STVN: Which Stock Is the Better Value Option?

Stevanato Group (STVN) Q3 Earnings Meet Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

TAK vs. STVN: Which Stock Is the Better Value Option?

TAK vs. STVN: Which Stock Is the Better Value Option?

Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

USNA or STVN: Which Is the Better Value Stock Right Now?

USNA vs. STVN: Which Stock Is the Better Value Option?

GRFS or STVN: Which Is the Better Value Stock Right Now?

GRFS vs. STVN: Which Stock Is the Better Value Option?

All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy

Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stevanato Group (STVN) Beats Q2 Earnings and Revenue Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 7.14% and 0.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Stevanato Group (STVN) Q1 Earnings Lag Estimates

Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?

Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stevanato Group S.p.A. (STVN) Hit a 52 Week High, Can the Run Continue?

Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Hold Teladoc Health (TDOC) Stock Now

Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.

Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?

Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Surging Earnings Estimates Signal Upside for Stevanato (STVN) Stock

Stevanato (STVN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 18.75% and 9.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Matches Q4 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -106.67% and 79.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ASRT vs. STVN: Which Stock Is the Better Value Option?

ASRT vs. STVN: Which Stock Is the Better Value Option?

ASRT vs. STVN: Which Stock Should Value Investors Buy Now?

ASRT vs. STVN: Which Stock Is the Better Value Option?

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?